BPTH – Bio-Path Holdings Inc
Float Short %
2.4
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
2.53
EPS This/Next Y
0.17
Price
0.07
Target Price
12
Analyst Recom
Performance Q
-76.24
Upside
N/A
Beta
0.19
Ticker: BPTH
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | BPTH | 0.0565 | N/A | N/A | 0 |
| 2026-01-26 | BPTH | 0.06 | N/A | N/A | 0 |
| 2026-01-27 | BPTH | 0.06 | N/A | N/A | 0 |
| 2026-01-28 | BPTH | 0.07 | N/A | N/A | 0 |
| 2026-01-29 | BPTH | 0.057 | N/A | N/A | 0 |
| 2026-01-30 | BPTH | 0.058 | N/A | N/A | 0 |
| 2026-02-02 | BPTH | 0.0695 | N/A | N/A | 0 |
| 2026-02-03 | BPTH | 0.0627 | N/A | N/A | 0 |
| 2026-02-04 | BPTH | 0.061 | N/A | N/A | 0 |
| 2026-02-05 | BPTH | 0.065 | N/A | N/A | 0 |
| 2026-02-06 | BPTH | 0.0572 | N/A | N/A | 0 |
| 2026-02-09 | BPTH | 0.058 | N/A | N/A | 0 |
| 2026-02-10 | BPTH | 0.066 | N/A | N/A | 0 |
| 2026-02-11 | BPTH | 0.066 | N/A | N/A | 0 |
| 2026-02-12 | BPTH | 0.058 | N/A | N/A | 0 |
| 2026-02-13 | BPTH | 0.058 | N/A | N/A | 0 |
| 2026-02-17 | BPTH | 0.058 | N/A | N/A | 0 |
| 2026-02-18 | BPTH | 0.0697 | N/A | N/A | 0 |
| 2026-02-20 | BPTH | 0.0681 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2026-01-26 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-01-27 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-01-28 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-01-29 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2026-01-30 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-02 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-03 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2026-02-04 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-05 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-06 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-09 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-10 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-11 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2026-02-12 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2026-02-13 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-17 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-18 | BPTH | 0.06 | 71.6 | - | -1.59 |
| 2026-02-19 | BPTH | 0.07 | 71.6 | - | -1.59 |
| 2026-02-20 | BPTH | 0.07 | 71.6 | - | -1.59 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
No data found
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.4
Avg. EPS Est. Next Quarter
-0.4
Insider Transactions
Institutional Transactions
Beta
0.19
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
33
Growth Score
19
Sentiment Score
87
Actual DrawDown %
100
Max Drawdown 5-Year %
-100
Target Price
12
P/E
Forward P/E
PEG
P/S
P/B
P/Free Cash Flow
EPS
-8.34
Average EPS Est. Cur. Y
-1.59
EPS Next Y. (Est.)
-1.42
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
110.6
Return on Equity vs Industry %
128.1
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.2
EBIT Estimation
Bio-Path Holdings, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 10
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
stock quote shares BPTH – Bio-Path Holdings Inc Stock Price stock today
news today BPTH – Bio-Path Holdings Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch BPTH – Bio-Path Holdings Inc yahoo finance google finance
stock history BPTH – Bio-Path Holdings Inc invest stock market
stock prices BPTH premarket after hours
ticker BPTH fair value insiders trading